読み込み中
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
終値時点
$15.46
−$0.17 · -1.09%
時間外
$17.00
+$1.54 · +9.96%
10月8日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
日中レンジ
現在 $15.46
52週レンジ
現在 $15.46
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
25
割高
センチメント
71
強気
リスク
38
中程度のリスク
モメンタム
71
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
日中レンジ
現在 $15.46
52週レンジ
現在 $15.46
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | — | 1894.3万 USD |
| 売上原価 | — | 30.6万 USD | — | — | — |
| 粗利益 | — | −30.6万 USD | — | — | 1894.3万 USD |
| 研究開発 | 1.87億 USD | 1.43億 USD | 1.48億 USD | 9194.8万 USD | 5775.1万 USD |
| 販売・一般管理 | 5424.6万 USD | 5371万 USD | 4249.3万 USD | 4018.9万 USD | 2914.6万 USD |
| 営業費用 | 2.42億 USD | 1.97億 USD | 1.91億 USD | −1.45億 USD | 8689.7万 USD |
| 受取利息 | 2221.2万 USD | 2966万 USD | 2162.7万 USD | 661.1万 USD | 47.7万 USD |
| 減価償却費と償却費 | 31.1万 USD | 30.6万 USD | 31万 USD | 9.3万 USD | 5.3万 USD |
| 営業利益 | −2.42億 USD | −1.97億 USD | −1.91億 USD | 1.45億 USD | −6795.4万 USD |
| 純利益 | −2.2億 USD | −1.67億 USD | −1.53億 USD | 1.11億 USD | −6557万 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$34.75
上昇余地（124.77%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI4314.01万0.00%2.3兆 USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM2489.19万0.03%776.97億 USD0.19%$277.57-0.05%
State Street SPDR S&P Biotech ETFXBI1970.01万0.20%100.75億 USD0.35%$149.29-0.63%
Vanguard Extended Market ETFVXF1373.86万0.01%954億 USD0.05%$233.13-0.15%
Vanguard Russell 2000 ETFVTWO767.77万0.04%180億 USD0.06%$112.1-0.10%
iShares Biotechnology ETFIBB556.83万0.05%104.14億 USD0.44%$200.48-1.41%
Dimensional - US Small Cap ETFDFAS534.66万0.02%336.6億 USD0.31%$78.10+0.23%
Fidelity Enhanced Small Cap ETFFESM484.59万0.07%64.1億 USD0.28%$45.25+0.07%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
